- About
- Advertise / Support
- Contact
- CancerNetwork.com
- TargetedOnc.com
- OncLive.com
- OncNursingNews.com
- Terms & Conditions
- Privacy
- Do Not Sell My Information
© 2023 MJH Life Sciences™ and CURE - Oncology & Cancer News for Patients & Caregivers. All rights reserved.
Latest Conference Articles
CAR-T Cell Therapy Continues to Impress in Myeloma Treatment
December 15th 2021, 7:00pm
American Society of Hematology Annual Meeting
Treatment with the CAR-T cell therapy ciltacabtagene autoleucel (cilta-cel) led to a 97.9% response rate at two years in patients with relapsed/refractory myeloma in a recent clinical trial.
Venclexta-Triplet Combo Appears Safe And Shows Deep Responses in Type of Relapsed/Refractory Multiple Myeloma
December 15th 2021, 2:00pm
American Society of Hematology Annual Meeting
Two different doses of Venclexta combined with Darzalex and the steroid dexamethasone elicited effective responses appeared safe in patients with t(11;14) relapsed/refractory multiple myeloma.
New Treatment Regimen May Reduce GvHD, the ‘Most Common and Feared Complication’ of Stem Cell Transplantation
December 14th 2021, 10:00pm
The addition of a drug commonly used to treat arthritis may reduce the risk of graft-versus-host-disease in patients who underwent haploidentical allogeneic stem cell transplant.
Calquence Remains Effective and Safe After 3 Years Compared With Standard of Care in Relapsed/Refractory Chronic Lymphocytic Leukemia
December 14th 2021, 8:00pm
Calquence, a next-generation BTK inhibitor, significantly prolonged survival compared with standard of care, along with no new side effects at three years in chronic lymphocytic leukemia. These findings also pertained to some patients with high-risk genetic features.
Imbruvica And Rituxan Bests Standard-of-Care Regimen in Patients With Previously Untreated CLL
December 14th 2021, 2:00pm
American Society of Hematology Annual Meeting
The data demonstrated that the combination of Imbruvica and Rituxan conferred superior progression-free survival results in patients with previously untreated chronic lymphocytic leukemia, compared with the chemotherapies fludarabine and cyclophosphamide plus Rituxan.
Novel Drug Plus Rituxan May Serve as ‘New Treatment Option’ for Relapsed/Refractory Lymphoma Subset
December 13th 2021, 10:00pm
American Society of Hematology Annual Meeting
The use of a novel drug combination yielded positive outcomes in patients with B-cell lymphomas for whom CAR-T cell therapy or stem cell transplant isn’t an option.
mRNA COVID-19 Vaccination Sparks Strong Antibody Response in Patients With AML and MDS
December 13th 2021, 9:00pm
American Society of Hematology Annual Meeting
Most patients with acute myeloid leukemia and myelodysplastic syndrome achieved strong antibody responses to COVID-19 vaccination, according to recent study results.
Ninlaro-Darzalex Combo Elicits Favorable Treatment Outcomes, Responses in Newly Diagnosed Multiple Myeloma
December 13th 2021, 8:00pm
American Society of Hematology Annual Meeting
Treatment with Ninlaro plus Darzalex and a low dose of the steroid dexamethasone was associated with favorable responses to treatment in non-transplant eligible, intermediate-fit patients with newly diagnosed multiple myeloma.
Patients With CLL Had Improved Quality of Life on Imbruvica Plus Rituxan
December 13th 2021, 2:30pm
American Society of Hematology Annual Meeting
Patients with chronic lymphocytic leukemia reported improved quality of life when treated with frontline Imbruvica and Rituxan, followed by continuous treatment with Imbruvica.
Novel Treatment Combination Shows Promising Results, Tolerable Side Effects in Multiple Myeloma
December 12th 2021, 10:00pm
American Society of Hematology Annual Meeting
Patients with relapsed or refractory multiple myeloma experienced a benefit after receiving Xpovio in combination with Darzalex, Velcade and the steroid dexamethasone.
Some Treatment Outcomes Do Not Differ Between Black and White Patients With Breast Cancer, But Disparities Persist
December 12th 2021, 8:00pm
Study results showed that pathologic complete response rates were not significantly different between Black and White patients with high-risk breast cancer, but disparities still exist for other treatment outcomes.
Kymriah May Be Safe and Effective in Children and Young Adults With Acute Lymphoblastic Leukemia Subtype
December 12th 2021, 5:11pm
American Society of Hematology Annual Meeting
The immunotherapy Kymriah offered similar benefits in patients younger than and older than 18 years with relapsed/refractory B-cell acute lymphoblastic leukemia.
Cancer Clinical Trial Enrollment Is Low in the US, and Patient Depression and Anxiety May Play a Role
December 12th 2021, 3:00pm
American Society of Hematology Annual Meeting
Researchers found that depression and anxiety may skew patient perceptions of participating in blood cancer clinical trials, thus contributing to low enrollment throughout the United States.
MRD-Guided Combination Treatment Appears Feasible in Patients With a Form of Relapsed/Refractory Leukemia
December 11th 2021, 10:00pm
American Society of Hematology Annual Meeting
Using the presence of minimal residual disease to direct Imbruvica plus Venclexta treatment appears to be a feasible option for patients with relapsed/refractory chronic lymphocytic leukemia.
Imbruvica, Venclexta Combo Offers Chemotherapy-Free Regimen for Patients with CLL
December 11th 2021, 6:34pm
American Society of Hematology Annual Meeting
Recent results demonstrated durable responses and no new side effects for Venclexta plus Imbruvica in pretreated chronic lymphocytic leukemia.
CAR-T Cell Therapy Bests Standard of Care in Health-Related Quality of Life for Patients With Lymphoma
December 11th 2021, 4:00pm
American Society of Hematology Annual Meeting
Patients with large B-cell lymphoma tended to have better quality of life that continued to improve over time after receiving Breyzani compared to those given standard of care.
Lynparza After Chemo May Not Greatly Impact Quality of Life in High-Risk Early Breast Cancer Subset
December 11th 2021, 3:00pm
Although patients treated with Lynparza after chemotherapy may experience side effects such as fatigue and nausea/vomiting, these symptoms resolved after treatment was completed in patients with high-risk early breast cancer.
Triplet Regimen Extends Time Before Brain, Spinal Cord Metastases Worsen in Patients With Breast Cancer
December 10th 2021, 10:00pm
A three-drug regimen was shown to lengthen the amount of time before cancer progressed to the central nervous system — known as central nervous system progression-free survival — in certain patients with breast cancer.
Dose Reduction of Xpovio Improves Safety and Optimizes Patient Outcomes in Myeloma
December 10th 2021, 8:00pm
American Society of Hematology Annual Meeting
In recent trial results, a dose reduction of Xpovio (selinexor) was associated with longer progression-free survival and duration of response while also reducing side effects in patients with multiple myeloma.
Experimental Drug Plus Chemo Boosts Survival in HER2-Positive Metastatic Breast Cancer
December 10th 2021, 5:00pm
The use of pyrotinib — an experimental drug — plus the chemotherapy capecitabine extended survival compared with Tykerb and capecitabine among patients with pretreated HER2-positive metastatic breast cancer.
Novel Drug Elicits Favorable Outcomes in Advanced, Metastatic TNBC
December 10th 2021, 2:00pm
Early-phase study results showed that treatment with a novel drug elicits promising outcomes in patients with advanced or metastatic triple-negative breast cancer.
Immunotherapy Before Surgery May ‘Increase the Chances’ Patients Are Cured of TNBC
December 9th 2021, 10:00pm
Clinical trial results show that adding Keytruda to chemotherapy prior to surgery for triple-negative breast cancer can improve outcomes and hopefully “increase the chances for patients to be cured,” according to an expert.
Study Confirms Adding Ibrance to Endocrine Therapy May Not Improve Outcomes in Early Breast Cancer
December 8th 2021, 10:00pm
The addition of Ibrance to endocrine therapy was not associated with preventing disease recurrence in patients with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative early breast cancer, according to final results of the phase 3 PALLAS trial.
Medication Used to Treat Diabetes Fails to Improve Breast Cancer Outcomes
December 8th 2021, 4:00pm
Researchers hypothesized that metformin — a medication that helps lower insulin levels in patients with diabetes and is associated with inducing weight loss — might improve breast cancer outcomes.
Novel Drug Has Potential to ‘Become New Standard of Care’ in Advanced, ER-Positive Breast Cancer
December 8th 2021, 2:00pm
The use of elacestrant, an investigational therapy, elicited a 30% reduction in the risk of disease progression or death compared with standard of care in a group of patients with estrogen receptor (ER)–positive, HER2-negative metastatic breast cancer.
Novel Drug Combo Doubles Progression-Free Survival in HER2-Negative Metastatic Breast Cancer
December 7th 2021, 10:00pm
Ibrance plus Faslodex improved progression-free survival in certain patients with metastatic breast cancer, compared with those who continued to receive an aromatase inhibitor.
Black Women With Breast Cancer Have a Higher Risk of Developing Lymphedema Than White Women
December 7th 2021, 4:00pm
Black race is associated with a 3.5-fold increased incidence of lymphedema in women with breast cancer treated with axillary lymph node dissection and radiotherapy, according to recent data.
Educated Patient® Breast Cancer Summit Outside of Therapy Session: November 13, 2021
November 13th 2021, 2:02pm
View the full CURE Educated Patient Breast Cancer Summit Outside of Therapy Session on demand.
Educated Patient® Breast Cancer Summit Novel Therapies Session: November 13, 2021
November 13th 2021, 2:01pm
View the full CURE Educated Patient Breast Cancer Summit Novel Therapies Session on demand.
Educated Patient® Breast Cancer Summit Multi-Disciplinary Approaches to Early-Stage Breast Cancer Session: November 13, 2021
November 13th 2021, 2:00pm
View the full CURE Educated Patient Breast Cancer Summit Multi-Disciplinary Approaches to Early-Stage Breast Cancer Session on demand.